Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans

Cancer Immunology Immunotherapy

Volumn 45, Issue 1, 1997, Pages 10-19

  Livingston, Philip O ^a   Ragupathi, Govindaswami ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER ANTIBODY; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM2; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; PHOSPHORYL LIPID A; PLACEBO; QS 21; TUMOR VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG MIXTURE; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CARBOHYDRATES; CLINICAL TRIALS; FORECASTING; HUMANS; IMMUNOTHERAPY;

EID: 0030765152     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050395     Document Type: Review

References (68)

1. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int J Cancer (in press)
2. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VI, Lloyd KO, Livingston PO (1997) Selection of blood group-related tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (in press)
3. Livingston PO, Sznol M (1997) Vaccine therapy for melanoma. In: Balch CM (ed) Cutaneous melanoma, 3rd edm. Lippincott, Philadelphia, (in press)
4. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Helling F, Ritter G, Oettgen HE, Old LJ (1994) Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 13:1036-1044
5. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL (1985) Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607
6. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins P, Sette A, Appella E, Rosenberg S (1995) Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in viva tumor regression. J Immunol 154:3961-3968
7. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal antibody IgG3 antibody detecting GD3 up, ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242-1246
8. Dippold WG, Bernhard H, Peter Dienes H, Meyer zum Buschenfelde KH (1988) Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies. Eur J Cancer Clin Oncol 24:S65-S67
9. Raymond J, Kirkwood J, Vlock D, Rabkin M, Day R, Whiteside T, Herberman R, Mascari R, Simon B (1988) A phase IB trial of murine monoclonal antibody R24 (anti-GD3) in metastatic melanoma (abstract). Proc Am Soc Clin Oncol 7:A958
10. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber IS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2 [see comments]. J Natl Cancer Inst 86:1159-1166
11. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, Rosenberg SA, Topalian SL (1994) In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 12: 1475-1483
12. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HE, Old LJ (1989) Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050
13. Longenecker BM, Reddish M, Miles D, MacLean GD (1993) Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res 2:151-161
14. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Nat Acad Sci USA 92: 8078-8082
15. Hoon DS, Yuzuki D, Hayashida M, Morton DL (1995) Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 154: 730-737
16. Livingston PO (1997) The case for melanoma vaccines that induce antibodies. In: Kirkwood JM (ed) Molecular diagnosis, prevention and treatment of melanoma. Marcel Dekker (in press)
17. Krementz ET, Samuels MS, Wallace JH et al (1971) Clinical experiences in immunotherapy of cancer. Surg Gynecol Obstet 33:209
18. Berd D, Murphy G, Maguire HC Jr, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867
19. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L (1990) Active-specific immunotherapy for melanoma. J Clin Oncol 8:856-869
20. Livingston PO, Oettgen HF, Old LJ (1982) Specific active immunotherapy in cancer therapy. In: Mihich E (ed) Immunological aspects of cancer therapeutics. Wiley, New York, pp 363-404
21. Livingston PO (1991) Active specific immunotherapy in the treatment of cancer. In: Ottegen HF (ed) Immunology and allergy clinics of North America. Human cancer immunology. II, vol 11. Saunders, London, pp 402-423
22. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashioff R (1993) Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 690:120-134
23. Laucius JF, Bodurtha AJ, Mastrangelo MJ, Bellet RE (1977) A phase 11 study of autologous irradiated tumor cells plus BCG in patients with metastatic melanoma. Cancer 40:2091-2093
24. Livingston PO, Zhang S, Lloyd K (1997) Carbohydrate vaccines that induce antibodies against cancer. Part I. Rationale. Cancer Immunol Immunother 45:1-9
25. Norrby E, Enders-Ruckle G, Ter Meulen V (1975) Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis 132:262
26. Oehen S, Hengartner H, Zinkernagel RM (1991) Vaccination for disease. Science 251:195-198
27. Weigle WO (1977) Autoimmunity: genetic, immunologic, virologic, and clinical aspects. In: Talal (ed) Academic Press, New York London, pp 141-170
28. Stuart JM, Cremer MA, Townes AS, et al (1982) Type II collagen-induced arthritis in rats. J Exp Med 155:1-10
29. Paterson PY (1983) LT/EAE and MS quest. Cell Immunol 82: 55-65
30. Allison AC (1977) Autoimmune diseases: concepts of pathogenisis and control. In: Talal N (ed) Autoimmunity: genetic, immunologic, virologic, and clinical aspects. Academic Press, New York London, pp 91-139
31. Rose NR (1981) Autoimmune disease. Sci Am 244:80
32. Lin R-H, Mamula MJ, Hardin JA, Janeway CA Jr (1991) Induction of autoreactive B cells allows priming of autoreactive Tcells. J Exp Med 173:1433-1439
33. Ritter G, Boosfeld E, Markstein E, Yu RK, Ren S, Oettgen HF, Old LJ, Livingston PO (1990) Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermild and chemically O-acelylated GD3. Cancer Res 50:1403-1410
34. Ritter G, Boosfeld E, Calves MJ, Oettgen HF, Old LJ, Livingston PO (1990) Antibody response after immunization with ganglio-sides GD3, GD3 lactones, GD3 amide and GD3 gangliosidol in the mouse. GD3 lactone I induces antibodies reactive with human melanoma. Immunobiology 182:32-43
35. Helling F, Shang Y, Calves M, Oettgen HF, Livingston PO (1994) Increased immunogenicity of GD3 conjugate vaccines: comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 54:197-203
36. Kensil CR, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146:431-437
37. Livingston PO, Koganty R, Longenecker BM, Lloyd KO, Calves M (1992) Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: augmentation of the response by Quil A and SAF-m adjuvants and analysis of the specificity of the responses. Vaccines Res 1:99-109
38. Toyokuni T, Dean B, Cai S, Boivin D, Hakomori S, Singhal AK (1994) Synthetic vaccines: synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins. J Am Chem Soc 116:395-396
39. Toyokuni T, Singhal AK (1995) Recent progress in synthetic vaccines based on tumor-associated carbohydrate antigens. Chem Soc Rev 24:231-242
40. Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty RR, Reddish M, Gandhi SS, Longenecker BM, Lloyd KO, Livingston PO (1995) Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55:3364-3368
41. Ragupathi G, Park TK, Zhang S, Kim IJ, Graeber K, Adluri S, Lloyd KO, Danishefsky SJ, Livingston PO (1997) Immunization of mice with the synthetic hexasaccaride GloboH results in antibodies against human cancer cells. Angew Chem 36:125-128
42. Kudryashov V, Ragupathi G, Kim LJ, Livingston PO, Danishefsky SJ, Lloyd KO (1997) Immunogenicity of synthetic Lewis Y oligosaccharide-protein conjugates in mice: towards the design of anti-cancer vaccines. Cancer Immunol Immunother (in press)
43. Singhal AK, Fohn M, Hakomori S (1991) Induction of Tn (α-N-acetylgalactosamine-O-serine/threoninine) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 51:1406-1411
44. Fung PYS, Madej M, Koganti R, Longenecker BM (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308-4314
45. Livingston PO (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:145-166
46. Livingston PO, Natoli EJ Jr, Jones Calves M, Stockert E, Oettgen HF, Old LJ (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Pro Natl Acad Sci USA 84:2911-2915
47. Hofstad T, Skaug N, Sveen K (1993) Stimulation of B lymphocytes by lipopolysaccharides from anaerobic bacteria. Clin Infect Dis 16[Suppl 4]:S200-205
48. Livingston PO, Zhang S, Walberg L, Ragupathi G, Helling F, Fleischer M (1997) Tumor cell reactivity medicated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies. Cancer Immunol Immunotherapy 43:324-330
49. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, Marciani D (1994) Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280
50. Ritter G, Boosfeld E, Adluri R, Calves M, Oettgen HF, Old LJ, Livingston PO (1991) Antibodies response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 48:379-385
51. Ritter G, Boosfeld E, Adluri R, Calves M, Ren S, Ye RK, Oettgen HF, Old LJ, Livingston PO (1995) Analysis of the antibody response to immunisation with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 62:1-5
52. Springer GF, Desai PR, Tegtmeyer H, Spencer BD, Scanlon EF (1993) Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. Ann NY Acad Sci 690:355-357
53. O'Boyle KP, Zamore R, Adluri S, Cohen A, Kemeny N, Welt S, Lloyd KO, Oettgen HF, Old LJ, Livingston PO (1992) Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res 52:5663-5667
54. McLean GD, Bowen-yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, Longenecker BM (1992) Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292-301
55. Adluri S, Helling F, Calves MJ, Lloyd KO, Livingston PO (1995) Immunogenicity of synthetic TF and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185-192
56. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM (1996) Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunotherapy 19:309-316
57. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R (1992) Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164
58. Mittelman A, Chen GZJ, Wong GU, Liu C, Hirai S, Ferrone S (1995) Human high molecular weight-melanoma associated antigen mimicry by mouse antiidiotypic monoclonal antibody MD2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1:705-713
59. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL (1994) Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54:3342-3345
60. Livingston PO, Kaelin E, Pinsky CM, Oettgen HF, Old LJ (1985) IV. Serologic response in stage II melanoma patients receiving allogeneic melanoma cell vaccines. Cancer 56:2194-2200
61. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254
62. MacLean GD, Reddish MA, Koganly RR, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19:59-68
63. Springer OF (1995) T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Cri Rev Oncog 6:57-85
64. Kundu SK, Marcus DM (1978) Production of antibodies to GD3. Fed Proc 37:1766
65. Gray GR (1978) Antibodies to carbohydrates: preparation of antigens by coupling carbohydrates to proteins by reductive amination with cyanoborohydride. Methods Enzymol 50:155-160
66. Helling F, Zhang A, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788
67. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, Fleming SA, Leiter EH, Shultz LD (1996) B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Igμnull mice. J Exp Med 184:2049-2053
68. Sopori ML, Donaldson LA, Savage SM (1990) T lymphocyte heterogeneity in the rat. III. Autoreactive T cells are activated by B cells. Cell Immun 128:427-437